Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2/3 1Phase 2 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 39NIH 3INDUSTRY 3UNKNOWN 2NETWORK 2

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Rectal Neoplasms 1Colorectal Neoplasms 1Colorectal Cancer Metastatic 1

Interventions

pembrolizumab 1019Carboplatin 959Paclitaxel 932Gemcitabine 793Cisplatin 748Docetaxel 682Bevacizumab 610Pemetrexed 502Nivolumab 486Cyclophosphamide 466Capecitabine 461Fluorouracil 417Dexamethasone 402Rituximab 372Oxaliplatin 347Injections 342atezolizumab 297Trastuzumab 297Leucovorin 286Cetuximab 282Irinotecan 266130-nm albumin-bound paclitaxel 252Prednisone 244Doxorubicin 240Ipilimumab 226Lenalidomide 220Fulvestrant 217fludarabine 214durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × raltitrexed × Clear all
NCT01959061 2017-03-13

TACE

Nanjing Chia-tai Tianqing Pharmaceutical

Phase 4 Unknown
320 enrolled
Gastrointestinal

Colorectal Cancer Metastatic

NCT00590278 2008-01-25

TOMUDEX

AstraZeneca

Phase 2 Completed
49 enrolled
Gastrointestinal

Rectal Neoplasms

NCT00234429 2007-12-18

A Phase 2 Study of Tomudex & Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma

AstraZeneca

Phase 2/3 Completed
74 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡